Article Sidebar

Submitted
Apr 21, 2021
Published
Apr 21, 2021
Download
PDF
Statistic
Read Counter : 50 Download : 41

Main Article Content

Abstract

Introduction


Glaucoma, “silent thief of sight” is a chronic, progressive optic neuropathy leading to optic nerve damage and visual field loss. Lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) is beneficial in reducing the risk for visual field loss in the long term. Various prostaglandin analogues have demonstrated consistent superiority over other therapies in terms of IOP reduction, however superiority amongst them remains inconclusive.


Objectives


To compare efficacy and safety of topical travoprost 0.004% versus latanoprost 0.005% in reducing intraocular pressure in patients with POAG.


Materials and methods


60 newly diagnosed patients of POAG who fulfilled the inclusion /exclusion criteria were randomised into two groups of 30 each to receive either travoprost or latanoprost once daily in the evening. Efficacy was measured in terms of reduction in IOP monitored at 4, 8 and 12 weeks from baseline.Safety was assessed by monitoring treatment emergent adverse drug reactions.


Results


Both travoprost and latanoprost effectively reduced IOP when compared to baseline. Mean IOP reduction from baseline to week 12 was 9.08 ± 1.93 mmHg (p<0.001), 7.96 ± 1.11 mmHg, (p<0.001) in travoprost and latanoprost groups respectively. There was significant reduction in IOP with travoprost when compared to latanoprost(8.86 ± 2.07 vs 7.71 ± 0.92, p=0.0003) at the end of 8 weeks and the same trend continued even at 12 weeks (9.08 ± 1.93 mmHg vs 7.96 ± 1.11 mmHg, p< 0.0002). Adverse drug reactions (ADR) were comparable in both the groups with conjunctival hyperaemia (21.6%) being the most common ADR.


Conclusion


Travoprost was found to be more efficacious in reducing IOP as early as 8 weeks as compared to latanoprost. There was an additional 1.12 mmHg reduction in IOP at the end of 12 weeks in comparison to latanoprost and it was well tolerated. Hence travoprost could be a favourable option for the treatment of primary open angle glaucoma.

Keywords

Latanoprost Travoprost Primary open angle glaucoma Intraocular pressure

Article Details

How to Cite
C R Jayanthi, Divyashree R N, & Sujatha R. (2021). A comparative study of efficacy and safety of topical travoprost 0.004% versus latanoprost 0.005% in the treatment of primary open angle glaucoma at a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 199-207. https://doi.org/10.61096/ijrpp.v6.iss2.2017.199-207
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Sihota R, Tandon R. The Glaucomas. In: Sihota R, Tandon R, editors. Parson’s Diseases of the eye. Noida: Elsevier, 21, 2011, 280-300.
  2. [2]. Saxena R, Singh D, Vashist P. Glaucoma: An Emerging Peril. Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine. 38(3), 2013, 135-137. doi:10.4103/0970-0218.116348.
  3. [3]. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clinical ophthalmology. 1(1), 2007, 11-24.
  4. [4]. Jill Autry, Elyse Chaglasian. Glaucoma and the New Prostaglandins. Review of cornea and contact lenses. 2012. Available at: http://www.reviewofcontactlenses.com/content/d/down_on_the.../34139/
  5. [5]. Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. CurrTher Res Clin Exp. 64(7), 2003, 389–400.
  6. doi: 10.1016/S0011- 393 X (03)00112-7.
  7. [6]. Varma R, Lee PP, Goldberg I, Kotak S. An Assessment of the Health and Economic Burdens of Glaucoma. American journal of ophthalmology. 152(4), 2011, 515-522. doi:10.1016/j.ajo.2011.06.004
  8. [7]. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 99(10), 1992, 1499-504.
  9. [8]. Leske MC, Wu SY, Honkanen R, Nemesure B, Schachat A, Hyman L, et al. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology. 114(6), 2007, 1058–1064
  10. [9]. Vajaranant TS, Nayak S, Wilensky JT, Joslin CE. Gender and glaucoma: what we know and what we need to know. Current opinion in ophthalmology. 21(2), 2010, 91-99. doi:10.1097/ICU.0b013e3283360b7e.
  11. [10]. Dave A, Bali SJ, Sharma R, Khurana AK, Gupta R, Dada Prevalence of diabetes mellitus and hypertension among Indian glaucoma patients and evaluation of systemic therapy. TIntOphthalmol. 33(5), 2013, 527-32.doi: 10.1007/s10792-013-9737-3.
  12. [11]. Wise LA, Rosenberg L, Radin RG, Mattox C, Yang EB, Palmer JR, et al. A prospective study of diabetes, lifestyle factors, and glaucoma among African-American women. Ann Epidemiol . 21, 2011, 430-9
  13. [12]. Fan BJ, Leung YF, Wang N, Lam SC, Liu Y, Tam OS, et al. Genetic and environmental risk factors for primary open-angle glaucoma. Chin Med J. 117, 2004, 706–10.
  14. [13]. The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration .American Journal of Ophthalmology , 130(4), 429 - 440
  15. [14]. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.Ophthalmology.106(4), 1999, 653-62
  16. [15]. Kass MA1, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, GordonMOThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.Arch Ophthalmol. 120(6), 2002, 701-13; discussion 829-30.
  17. [16]. Leske MC, Heijl A, Hyman L, Bengtsson B. Ophthalmology.Early Manifest Glaucoma Trial: design and baseline data.106(11), 1999, 2144-53
  18. [17]. Kelly CR, Williams GW, Sharif NA.Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J PharmacolExpTher. 304, 2003, 238–45.
  19. [18]. Yousufzai SY, Ye Z, Abdel-Latif AA. Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species.Exp Eye Res. 63(3), 1996, 305-10
  20. [19]. Zhan GL, Camras CB, Opere C, Tang L, Ohia SE. Effect of prostaglandins on cyclic AMP production in cultured human ciliary muscle cells. J OculPharmacolTher. 14(1), 1998, 45-55.
  21. [20]. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci, 38, 1997, 2214–23.
  22. [21]. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. CurrOpinOphthalmol, 11, 2000, 112–15.
  23. [22]. Netland P A, Landry T, Sullivan E K, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol . 132 (4), 2001, 472-84.
  24. [23]. Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R.A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.Clin Ther. 29(9), 2007, 1915-23.
  25. [24]. Sawada A, Yamamoto T, Takatsuka N. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefes Arch ClinExpOphthalmol. 250(1), 2012, 123-9. doi: 10.1007/s00417-011-1762-1
  26. [25]. Parrish RK, Palmberg P, Sheu WP.A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol, 135, 2003, 688–703.
  27. [26]. Cheng JW, Xi JL, Wei RL, Cai JP, Li Y. Effects of travoprost in the open angle glaucoma or ocular hypertension: A systematic review and meta-analysis. Current therapeutic research.70(4), 2009, 335–350.doi:10.1016/j.curtheres.2009.08.006.